NM_005249.5(FOXG1):c.217C>T (p.Gln73Ter)

AAV-mediated FOXG1 gene replacement is being pursued as a potential therapeutic strategy for FOXG1 syndrome, driven by organizations including the FOXG1 Research Foundation. However, FOXG1 is critically dosage-sensitive: both haploinsufficiency and overexpression (as seen in FOXG1 duplication cases and 14q12 duplications) cause severe neurodevelopmental phenotypes. The c.217C>T (p.Gln73Ter) nonsense variant creates a premature stop at residue 73, upstream of the forkhead domain (FHD, residues ~181-275), producing a severely truncated, non-functional protein. This is a clear loss-of-function allele amenable to gene replacement, provided expression can be tightly controlled.

FOXG1 encodes a winged-helix transcription factor essential for telencephalic development, GABAergic interneuron specification, and postnatal neuronal survival. The forkhead domain (FHD) mediates DNA binding and is located at residues ~181-275 — the p.Gln73Ter truncation eliminates this entire domain along with downstream transcriptional regulatory regions. FOXG1 syndrome presents with severe microcephaly, absent speech, dyskinesia, and corpus callosum abnormalities, typically manifesting by 3-6 months of age. The FOXG1 Research Foundation has funded preclinical gene therapy programs, and AAV-FOXG1 vectors have been tested in Foxg1 heterozygous knockout mice. Intracerebroventricular (ICV) or intrathecal AAV9 delivery is the likely route given that FOXG1 is primarily expressed in the forebrain. Key preclinical work has demonstrated partial phenotypic rescue in mouse models, though the therapeutic window for a neurodevelopmental transcription factor remains a central question.

FOXG1 dosage sensitivity is the primary obstacle: FOXG1 duplications cause intellectual disability and epilepsy, meaning that even modest overexpression could be harmful. Unlike structural proteins where excess may be tolerated, transcription factor dosage must be precisely controlled — a challenge no current AAV regulatory element has fully solved. Developmental timing is critical: FOXG1 functions primarily during embryonic forebrain patterning, and postnatal gene replacement may only address FOXG1 roles in neuronal maintenance rather than restoring mis-patterned circuits. BBB penetration and widespread forebrain transduction are technically demanding. No clinical trial for FOXG1 gene therapy has been registered as of the knowledge cutoff. The mouse model (Foxg1+/-) does not fully recapitulate human FOXG1 syndrome severity. The c.217C>T variant specifically has not been studied in any preclinical gene therapy experiment.

AAV9-mediated FOXG1 gene replacement therapy (FRF-001, using scAAV9 with hSyn1 promoter) is the most clinically advanced therapeutic approach for this early nonsense variant. FRF-001 has received FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, with clinical trials expected in 2026. Preclinical data in Q84P knock-in mice show rescue of locomotor and behavioral phenotypes following postnatal intracerebroventricular delivery. Because c.217C>T creates a premature stop at codon 73 — well before the forkhead DNA-binding domain — the truncated protein is entirely nonfunctional, making exogenous gene delivery the most straightforward rescue strategy for this variant.

Behavioral efficacy study (bioRxiv, April 2025): ICV injection of scAAV9.hSyn1-opthFOXG1 at P6 in Q84P mice rescued open-field activity, running wheel locomotion, and multiple SmartCube behavioral endpoints. A separate 2024 study demonstrated that postnatal AAV-FOXG1 injection in neonatal Foxg1-heterozygous mice rescued callosal axon connectivity and substantially recovered the corpus callosum. However, a follow-up safety study (bioRxiv, October 2025) revealed that early P2 treatment exacerbated certain motor phenotypes in female but not male mice, indicating sex-specific dose-response effects. CRISPRa-based upregulation of endogenous FOXG1 from the wild-type allele has also shown proof-of-concept in patient-derived cells (NAR Molecular Medicine, 2025), achieving 1.68–2.35-fold upregulation with no detectable off-target effects. PLP1-targeting ASOs have been shown to normalize grip strength deficits in Foxg1-mutant mice by correcting downstream PLP1 overexpression (PMID: 39409184).

The central challenge for FOXG1 gene therapy is extreme dosage sensitivity: both haploinsufficiency and overexpression of FOXG1 cause disease (duplications are associated with autism-like phenotypes and immune dysregulation). The therapeutic window between insufficient and excessive FOXG1 expression is narrow and may vary by brain region and developmental stage. The October 2025 preclinical finding of sex-specific adverse effects at early treatment timepoints adds significant complexity to clinical dosing. Not all behavioral phenotypes were rescued in preclinical models (contextual fear conditioning was not improved). Brain delivery and biodistribution remain challenging — achieving uniform transduction across cortical and subcortical regions with a single ICV injection is not guaranteed. The small patient population (~3 per 100,000 births) necessitates international collaboration for adequately powered trials. For this specific nonsense variant, suppressor tRNA technology is an exciting mutation-class-specific alternative under early exploration by the FOXG1 Research Foundation, but no FOXG1-specific readthrough data exist yet.